What is Chardan Capital’s Forecast for PRQR FY2024 Earnings?

ProQR Therapeutics (NASDAQ:PRQR) – Chardan Capital decreased their FY2024 earnings per share estimates for shares of ProQR Therapeutics in a report released on Sunday, November 10th. Chardan Capital analyst K. Nakae now forecasts that the biopharmaceutical company will earn ($0.31) per share for the year, down from their previous estimate of ($0.28). The consensus estimate for ProQR Therapeutics’ current full-year earnings is ($0.33) per share. Chardan Capital also issued estimates for ProQR Therapeutics’ FY2025 earnings at ($0.34) EPS.

Several other brokerages also recently commented on PRQR. Raymond James upgraded ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and increased their price target for the company from $6.00 to $14.00 in a report on Tuesday, October 29th. HC Wainwright lifted their target price on shares of ProQR Therapeutics from $5.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, November 8th. One analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, ProQR Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $7.13.

ProQR Therapeutics Price Performance

Shares of PRQR stock opened at $3.98 on Wednesday. The stock’s 50 day simple moving average is $2.55 and its 200 day simple moving average is $2.12. ProQR Therapeutics has a twelve month low of $1.18 and a twelve month high of $4.62.

Institutional Investors Weigh In On ProQR Therapeutics

Hedge funds have recently modified their holdings of the business. EP Wealth Advisors LLC acquired a new position in ProQR Therapeutics during the 1st quarter valued at $26,000. Acadian Asset Management LLC acquired a new position in shares of ProQR Therapeutics during the first quarter valued at about $56,000. BNP Paribas Financial Markets lifted its stake in shares of ProQR Therapeutics by 120.1% in the first quarter. BNP Paribas Financial Markets now owns 35,001 shares of the biopharmaceutical company’s stock valued at $80,000 after buying an additional 19,100 shares during the period. OneDigital Investment Advisors LLC grew its position in ProQR Therapeutics by 37.0% during the third quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 15,550 shares in the last quarter. Finally, Ikarian Capital LLC increased its stake in ProQR Therapeutics by 2.3% during the first quarter. Ikarian Capital LLC now owns 483,583 shares of the biopharmaceutical company’s stock valued at $1,098,000 after acquiring an additional 10,958 shares during the period. 32.65% of the stock is owned by institutional investors.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).